Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Updates on CPX-351: real world experiences and studies in MDS

Thomas Cluzeau • 13 Dec 2021
ASH 2021
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes CPX-351 Cytarabine Daunorubicin

CPX-351 is a dual-drug liposomal formulation of cytarabine and daunorubicin, approved by the FDA for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) with myelodysplasia-related changes (AML-MRC) and therapy-related AML. Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the latest news on CPX-351, including real-world experiences and trials in myelodysplastic syndrome (MDS). This interview took place at during 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Thomas Cluzeau

1:40
Highlights in LR-MDS at the ASH 2023 meeting
Thomas Cluzeau • 9 Dec 2023
1:55
Long-term real-world experience of CPX-351 in patients with t-AML and MRC-AML
Thomas Cluzeau • 9 Dec 2023
2:17
VENTOGRAFT trial: AZA, VEN, and DLI in patients with MDS and AML who have relapsed following alloSCT
Thomas Cluzeau • 10 Dec 2023
Novel targets, combinations & treatments
Eunice Wang et al. • 4 Sep 2023

Related Videos

1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals